UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Nature communications, 2023-01, Vol.14 (1), p.252-252, Article 252

2023

Volltextzugriff (PDF)

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Nature communications, 2024-03, Vol.15 (1), p.2790-2790, Article 2790

2024

Volltextzugriff (PDF)

Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Journal of Nuclear Medicine, 2023-03, Vol.64 (3), p.349-350

2023

Volltextzugriff (PDF)

Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer

Targeting the DNA Damage Response for Cancer Therapy, 2023, Vol.186, p.103-124

2023

Volltextzugriff (PDF)

Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth

Nature biomedical engineering, 2022-03, Vol.6 (3), p.257-266

2022

Volltextzugriff (PDF)

Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-136-LB-136

2016

Volltextzugriff (PDF)

Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5018-5018

2019

Volltextzugriff (PDF)

Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.27-27

2024

Volltextzugriff (PDF)

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT161-CT161

2019

Volltextzugriff (PDF)

A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS219-TPS219

2022

Volltextzugriff (PDF)

Abstract 3521: Transcriptome analysis of TCGA prostate cancer samples identifies an association of poorer survival and aggressive disease biology with CDC-like kinase (CLK) expression and spliceosome regulation

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3521-3521

2020

Volltextzugriff (PDF)

PP03 Presentation Time: 9:20 AM

Brachytherapy, 2022-11, Vol.21 (6), p.S21

2022

Volltextzugriff (PDF)

PP03 Presentation Time: 9:20 AM: Patterns of Failure for Salvage HDR Prostate Brachytherapy in the Prostate PET Imaging Era

Brachytherapy, 2022-11, Vol.21 (6), p.S21-S21

2022

Volltextzugriff (PDF)

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.178-178

2023

Volltextzugriff (PDF)

Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.108-108

2023

Volltextzugriff (PDF)

Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.203-203

2023

Volltextzugriff (PDF)

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS266-TPS266

2020

Volltextzugriff (PDF)

Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

The Journal of nuclear medicine (1978), 2023-03, Vol.64 (3), p.349-350

2023

Volltextzugriff (PDF)

Reply by Authors

The Journal of urology, 2021-05, Vol.205 (5), p.1274-1274

2021

Volltextzugriff (PDF)

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS186-TPS186

2021

Volltextzugriff (PDF)

Patient outcomes after therapy with 177 Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.87-87

2024

Volltextzugriff (PDF)

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.134-134

2024

Volltextzugriff (PDF)

Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.326-326

2024

Volltextzugriff (PDF)

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5098-TPS5098

2022

Volltextzugriff (PDF)

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS195-TPS195

2022

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer

Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth

Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer

Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC)

Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC)

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Abstract 3521: Transcriptome analysis of TCGA prostate cancer samples identifies an association of poorer survival and aggressive disease biology with CDC-like kinase (CLK) expression and spliceosome regulation

PP03 Presentation Time: 9:20 AM

PP03 Presentation Time: 9:20 AM: Patterns of Failure for Salvage HDR Prostate Brachytherapy in the Prostate PET Imaging Era

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC)

Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences

Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Reply by Authors

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Patient outcomes after therapy with 177 Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)

Aktive Filter

Suchergebnisse filtern